The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit

描述(由申请人提供)：奥斯瓦尔多·克鲁斯基金会(Fiocruz)治疗和预防艾滋病毒/艾滋病临床试验股(FioTrials)是一个位于巴西里约热内卢的多学科综合研究中心，与Pesquisa Clinica Evandro Chagas临床研究网站(IPEC CRS)合作，与FioTrials CTU和IPEC CRS一起为高危人群和艾滋病毒感染者提供护理，并满足某些被剥夺公民权的人群的需求，包括男性男男性行为者(MSM)、变性女性、少数族裔、妇女、贫困和/或未受教育者。FioTrials CTU和IPEC CRS拥有独特的优势，可以提供艾滋病临床试验小组(ACTG)、艾滋病毒预防试验网络(HPTN)和杀微生物剂试验网络(MTN)，其中包括一批领先的研究人员；与致力于公共卫生研究的国际公认的政府组织Fiocruz的合作伙伴关系；以及与每个网络的科学议程相互补充的参与人群。我们这项研究的目标是：1)评估和实施预防男男性接触者、跨性别妇女和妇女感染艾滋病毒的综合策略(治疗和行为)；2)评估直肠杀菌剂对男男性接触者的安全性、有效性和实用性；3)评估针对艾滋病毒合并感染者结核病的新型诊断、技术、预防和治疗干预措施；4)评估丙型肝炎的新型治疗策略，尤其是针对HI合并感染的人群；以及5)评估新型疗法，改进现有的艾滋病毒治疗策略和预防合并发病。这些目标的实现将归功于FioTrials CTU出色的基础设施、其CRS及其以社区为重点的研究战略。

DESCRIPTION (provided by the applicant): The Oswaldo Cruz Foundation (FIOCRUZ) Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials), is a multidisciplinary, integrated research center based in Rio de Janeiro, Brazil that is partnered with the Institute de Pesquisa Clinica Evandro Chagas Clinical Research Site (IPEC CRS), Together the FioTrials CTU and IPEC CRS provide care for both "at-risk" and HIV infected persons and cater to the needs of certain disenfranchised populations, including men who have sex with men (MSM), transgender women, racial minorities, women, and those who are poverty stricken and/or uneducated. The FioTrials CTU and IPEC CRS have unique strengths to offer the AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN) and Microbicide Trials Network (MTN), including a cadre of leading researchers; a partnership with FIOCRUZ, an internationally-recognized governmental organization dedicated to public health research; and a participant population that compliments the scientific agendas of each network. The goal of our research is to 1) evaluate and implement integrated strategies (therapeutic and behavioral) to prevent HIV acquisition in MSM, transgender women and women; 2) evaluate the safety, efficacy and utility of rectal microbicides for our MSM population; 3) evaluate novel diagnostics, technologies, prevention and treatment interventions for tuberculosis in HIV co-infected individuals; 4) evaluate novel treatment strategies for hepatitis C, particularly for those with HI co-infection; and 5) assess novel therapeutics and improve existing HIV treatment strategies and prevent co-morbidities. Achievement of these objectives will be attributed to the outstanding infrastructure of the FioTrials CTU, its CRS and its community-focused research strategies.